drugset / Trial / NCT01536938

LEO 90100 in the Treatment of Psoriasis Vulgaris

NCT01536938

Phase 2 Completed 303 enrolled LEO Pharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate whether LEO 90100, calcipotriol and betamethasone are effective in the treatment of psoriasis vulgaris.

Timeline

Start
2012-05
Primary completion
2012-09
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Betamethasone Other / unclassified 0.05 % Topical
Comparator Calcipotriol Small molecule 0.005 % Topical

Indications